Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research is being done to evaluate the effects of a sleeping pill (eszopiclone, Lunesta)in patients with arthritis of the knee who also suffer from chronic insomnia. This study will test whether Lunesta improves sleep, pain sensitivity, and daytime symptoms in patients with knee pain.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eszopiclone | Experimental | Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks |
|
| Placebo | Placebo Comparator | 3mg placebo capsule, once daily at bedtime for 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | 3mg placebo capsule, once daily at bedtime |
| |
| Eszopiclone |
| Measure | Description | Time Frame |
|---|---|---|
| Wake After Sleep Onset (WASO) | Total minutes of wakefulness recorded after sleep onset. (Recorded in Daily Sleep Diary) WASO= time awake in the middle of the night, not counting SL or time in bed after awakening. Recorded in minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Time in Bed | Total time in bed, in minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Sleep Latency (SL) | Sleep Latency: time taken to fall asleep, in minutes (as recorded in daily sleep diary) | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Number of Awakenings | As recorded in daily sleep diary | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Total Sleep Time (TST) | minutes spent asleep as recorded in daily sleep diary | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Sleep Efficiency (SE) | [(TST/ TIB)X 100], (%) as recorded in daily sleep diary | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Sleep Quality (SQ) | As recorded in daily sleep diary. Visual analog scales (VAS) Sleep Quality Ratings 0-100, 0= extremely poor sleep quality, (shallow and unrefreshing) and 100=excellent sleep quality (deep and refreshing) |
| Measure | Description | Time Frame |
|---|---|---|
| Heat Pain Threshold | Contact heat stimuli at non tissue damaging temperatures were delivered using computer driven, peltier-element-based stimulator (Medoc, TSA II), with a 9 cm2 probe applied to the left forearm. The thermode was affixed snugly via Velcro straps to ensure even skin contact and repositioned to an adjacent site after each trial to minimize sensitizationHPTh was assessed on the left ventral forearm using an ascending method of limits paradigm; from a non-painful 32°C baseline, the temperature was steadily increased at 0.5°C/sec. Two trials of heat pain threshold were conducted. Averages of both trials are presented from respective time point below. Subjects push a button when the stimulus "first feels painful" The temperature (degrees Celsius) at the time button is pushed is automatically recorded. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael T. Smith, Ph.D. | Johns Hopkins University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | United States |
105 were assessed for eligibility. 75 were excluded based on not meeting inclusion criteria. 30 were randomized to one of 2 arms. One subject after randomization ( to placebo condition) was determined to be ineligible due to failing sleep apnea entry criteria. They were removed from the study and did not contribute to baseline data.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Eszopiclone | Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks Eszopiclone: 3mg capsule, once daily at bedtime |
| FG001 | Placebo | 3mg placebo capsule, once daily at bedtime for 12 weeks Placebo: 3mg placebo capsule, once daily at bedtime |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Baseline characteristics were only calculated for the 29 participants above. One subject after randomization ( to placebo condition) was determined to be ineligible due to failing sleep apnea entry criteria. They were removed from the study and did not contribute to baseline data.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Eszopiclone | Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks Eszopiclone: 3mg capsule, once daily at bedtime |
| BG001 | Placebo | 3mg placebo capsule, once daily at bedtime for 12 weeks Placebo: 3mg placebo capsule, once daily at bedtime |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Wake After Sleep Onset (WASO) | Total minutes of wakefulness recorded after sleep onset. (Recorded in Daily Sleep Diary) WASO= time awake in the middle of the night, not counting SL or time in bed after awakening. Recorded in minutes | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
Participants were followed for study duration, up to 12 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | 3mg placebo capsule, once daily at bedtime for 12 weeks Placebo: 3mg placebo capsule, once daily at bedtime |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Restlessness, anxiety, agitation | Psychiatric disorders |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Michael Smith, PhD, Associate Professor of Psychiatry, Director of Behavioral Medicine | Johns Hopkins University School of Medicine | 410-550-7000 | msmith62@jhmi.edu |
Not provided
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069582 | Eszopiclone |
| ID | Term |
|---|---|
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011719 | Pyrazines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
3mg capsule, once daily at bedtime |
|
| Mean of baseline, 6 week follow-up, and 12 week follow-up |
| WASO as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. WASO recorded by device = total minutes of wakefulness after sleep onset, in minutes. | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| TST as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. TST recorded by device = total minutes spent asleep | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Sleep Efficiency as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. Sleep efficiency is the index of sleep percentage recorded, equal to total sleep time divided by the time in bed X 100 = X%. | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Sleep Latency as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. Sleep latency is the time taken to fall asleep, or equal to lights out- sleep onset (sleep onset: time when sleep is first scored after lights out, first scorable epoch). | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Insomnia Severity Index (ISI) Mean Total Scores | The ISI is made up of 7 questions, each possible of earning a score of 0-4, making the total range 0-28, where 0 indicates no severity/no problem with sleep and therefore no insomnia, or 28, being very severe with the highest level of insomnia | Mean of baseline, 6 week follow-up, and 12 week follow-up |
| Diffuse Noxious Inhibitory Control (DNIC) Index Scores | PPTh:a somedic algometer's 1cm2 rubber probe was placed over muscle belly, with pressure increasing steadily at constant rate (30kPA/Sec), until subject indicated that s/he "first felt pain." PPTh ratings were obtained on right brachioradialis & right trapezius in a random order (average was taken from both areas at each time point). During each cold pressor task, participants immersed contralateral hand (left) up to wrist, in a circulating cold water bath maintained at 4°C. 20 seconds after commencing hand immersion, PPTh was re-assessed on either right brachioradialis or right trapezius (the same site as baseline assessment). After PPTh assessment, participants removed hands from water. DNIC was measured as the % change in PPTh during cold pressor, relative to baseline PPTh [i.e., (mean PPTh during cold pressor / mean PPTh prior to cold pressor)*100]. Increase in PPTh during cold pressor (i.e., percentage scores above 100) reflects normal functioning of pain-inhibitory processes. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Temporal Summation (TS) | TS :maximum windup pain rating - first windup pain rating (0-100). Contact heat stimuli at non tissue damaging temperatures were delivered using computer driven, peltier-element-based stimulator (Medoc, TSA II), with a 9 cm2 probe applied to left forearm. In order to assess temporal summation, three sequences of 10 heat pulses each (with stimulus temperatures of 46 degrees C, 48 degrees C, and 50 degrees C, in random order) were applied to left dorsal forearm. The thermode remains in fixed position during administration of 10 heat pulses that constitute a sequence. Within each sequence, successive thermal pulses at a given temperature are delivered for a duration of approximately 0.5 sec each, with a 2.5-sec inter-pulse interval. The rate of rise & fall of the thermode temp. is set at the device max .of 10 degrees C / S. Subjects verbally rate the perceived intensity of each thermal pulse on a 0-100 rating scale & may terminate the procedure at any time.100=max tolerable intensity | Mean of baseline, 6 week follow-up and 12 week follow-up at 46, 48, and 50 degrees C |
| Mean Level of Pain Experienced Throughout the Day | Assessed using a Daily Pain Diary with a scale 0-100, 0 being no pain, 100 being the most severe/intense | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Pain as Assessed by the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Pain Severity Subscale | The WOMAC is a quality of scale life made up of three domains, pain, stiffness, and disability which each comprising of 5, 2, and 7 questions, respectively. A VAS was used for each subscale. Pain was assessed on a scale of 0-100, with 0 being absolutely no pain and 100 being maximum pain. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Mean of baseline, 6 week follow-up and 12 week follow-up |
| Heat Pain Tolerance (HPTOL) | Contact heat stimuli at non tissue damaging temperatures were delivered using computer driven, peltier-element-based stimulator (Medoc, TSA II), with a 9 cm2 probe applied to the left forearm. The thermode was affixed snugly via Velcro straps to ensure even skin contact and repositioned to an adjacent site after each trial to minimize sensitization. HPTOL was assessed on the left ventral forearm using an ascending method of limits paradigm; from a non-painful 32°C baseline, the temperature was steadily increased at 0.5°C/sec. Two trials of HPTOL were conducted. An average of both trials at each respective time point is presented below. Subjects push a button when the stimulus "becomes intolerable." The temperature (degrees Celsius) at the time button is pushed to terminate the stimulation is automatically recorded. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Pressure Pain Threshold | A Somedic algometer was used to assess pressure pain threshold (PPTh) similar to previous studies. The algometer's 1cm2 rubber probe was placed over the muscle belly, with the pressure increased steadily at a constant rate (30kPA/Sec), until the subject indicated that s/he "first felt pain." PPTh was assessed 2 times each, bilaterally, at (in a randomized order) the masseter muscle trapezius muscle, and at the proximal third of the brachioradialis muscle (forearm). The scores from each location were averaged for each participant at that respective time point. The same site was never stimulated consecutively. At least 90 s were maintained between successive stimuli | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Quality of Life as Assessed by the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Disability Subscale | The WOMAC is a quality of scale life made up of three domains, pain, stiffness, and disability which each comprising of 5, 2, and 7 questions, respectively. A VAS was used for each subscale. Disability was assessed on a VAS of 0-100, with 0 being absolutely no disability and 100 being maximum disability. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Quality of Life as Assessed by the Short Form-36 (SF-36) Physical Health Component Summary | The SF-36 is a broad, well normed measure of quality of life, comprised of 36 questions aggregated into 8 domains/dimensions. The Physical Component Summary was used here as a global index of physical health functioning. Scale 0-100, with 0 being worst functional level, 100 being the best. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Quality of Life as Assessed by the Short Form-36 (SF-36) Mental Health Component Summary | The SF-36 is a broad, well normed measure of quality of life, comprised of 36 questions aggregated into 8 domains/dimensions. The Mental Component Summary was used here as a global index of mental health functioning. Scale 0-100, with 0 being worst functional level, 100 being the best. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| Joint Stiffness as Assessed by the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Joint Stiffness Subscale | The WOMAC is a quality of scale life made up of three domains, pain, stiffness, and disability which each comprising of 5, 2, and 7 questions, respectively. A VAS was used for each subscale. Joint Stiffness was assessed on a VAS scale of 0-20, with 0 being no joint stiffness, and 20 being maximum stiffness. | Mean of baseline, 6 week follow-up and 12 week follow-up |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Kellgren Lawrence OA grade | grade 0: no radiographic features of osteoarthritis (OA) are present grade 1: doubtful joint space narrowing (JSN) and possible osteophytic lipping grade 2: definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph grade 3: multiple osteophytes, definite JSN, sclerosis, possible bony deformity grade 4: large osteophytes, marked JSN, severe sclerosis and definite bony deformity | Mean | Standard Deviation | units on a scale |
|
| Kellgren Lawrence OA grade >=3 in either knee | grade 0: no radiographic features of OA are present grade 1: doubtful joint space narrowing (JSN) and possible osteophytic lipping grade 2: definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph grade 3: multiple osteophytes, definite JSN, sclerosis, possible bony deformity grade 4: large osteophytes, marked JSN, severe sclerosis and definite bony deformity | Number | participants |
|
| BMI | Mean | Standard Deviation | kg/m^2 |
|
| Duration of OA | Mean | Standard Deviation | months |
|
|
|
| Primary | Time in Bed | Total time in bed, in minutes | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Sleep Latency (SL) | Sleep Latency: time taken to fall asleep, in minutes (as recorded in daily sleep diary) | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Number of Awakenings | As recorded in daily sleep diary | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | number of awakenings | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Total Sleep Time (TST) | minutes spent asleep as recorded in daily sleep diary | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Sleep Efficiency (SE) | [(TST/ TIB)X 100], (%) as recorded in daily sleep diary | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | percentage of efficient sleep | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Sleep Quality (SQ) | As recorded in daily sleep diary. Visual analog scales (VAS) Sleep Quality Ratings 0-100, 0= extremely poor sleep quality, (shallow and unrefreshing) and 100=excellent sleep quality (deep and refreshing) | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | WASO as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. WASO recorded by device = total minutes of wakefulness after sleep onset, in minutes. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | TST as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. TST recorded by device = total minutes spent asleep | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Sleep Efficiency as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. Sleep efficiency is the index of sleep percentage recorded, equal to total sleep time divided by the time in bed X 100 = X%. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | percentage of time asleep | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Sleep Latency as Assessed by Actigraphy | Subjects wore a Mini Mitter Actiwatch for two continuous weeks at each assessment periods to provide an objective index compared to the assessments made by daily sleep journal. Device is lightweight and worn on non-dominant wrist and contains and omni-directional accelerometer. The accelerometer records the occurrence and degree of motion with a minimal resultant force of .01g. Data are stored as activity counts within a specified epoch. Sleep latency is the time taken to fall asleep, or equal to lights out- sleep onset (sleep onset: time when sleep is first scored after lights out, first scorable epoch). | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | minutes | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Insomnia Severity Index (ISI) Mean Total Scores | The ISI is made up of 7 questions, each possible of earning a score of 0-4, making the total range 0-28, where 0 indicates no severity/no problem with sleep and therefore no insomnia, or 28, being very severe with the highest level of insomnia | Data was not included for all participants, as some were unable to complete the task. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up, and 12 week follow-up |
|
|
|
| Primary | Diffuse Noxious Inhibitory Control (DNIC) Index Scores | PPTh:a somedic algometer's 1cm2 rubber probe was placed over muscle belly, with pressure increasing steadily at constant rate (30kPA/Sec), until subject indicated that s/he "first felt pain." PPTh ratings were obtained on right brachioradialis & right trapezius in a random order (average was taken from both areas at each time point). During each cold pressor task, participants immersed contralateral hand (left) up to wrist, in a circulating cold water bath maintained at 4°C. 20 seconds after commencing hand immersion, PPTh was re-assessed on either right brachioradialis or right trapezius (the same site as baseline assessment). After PPTh assessment, participants removed hands from water. DNIC was measured as the % change in PPTh during cold pressor, relative to baseline PPTh [i.e., (mean PPTh during cold pressor / mean PPTh prior to cold pressor)*100]. Increase in PPTh during cold pressor (i.e., percentage scores above 100) reflects normal functioning of pain-inhibitory processes. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | percentage change of PPTh | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Primary | Temporal Summation (TS) | TS :maximum windup pain rating - first windup pain rating (0-100). Contact heat stimuli at non tissue damaging temperatures were delivered using computer driven, peltier-element-based stimulator (Medoc, TSA II), with a 9 cm2 probe applied to left forearm. In order to assess temporal summation, three sequences of 10 heat pulses each (with stimulus temperatures of 46 degrees C, 48 degrees C, and 50 degrees C, in random order) were applied to left dorsal forearm. The thermode remains in fixed position during administration of 10 heat pulses that constitute a sequence. Within each sequence, successive thermal pulses at a given temperature are delivered for a duration of approximately 0.5 sec each, with a 2.5-sec inter-pulse interval. The rate of rise & fall of the thermode temp. is set at the device max .of 10 degrees C / S. Subjects verbally rate the perceived intensity of each thermal pulse on a 0-100 rating scale & may terminate the procedure at any time.100=max tolerable intensity | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up at 46, 48, and 50 degrees C |
|
|
|
| Primary | Mean Level of Pain Experienced Throughout the Day | Assessed using a Daily Pain Diary with a scale 0-100, 0 being no pain, 100 being the most severe/intense | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Primary | Pain as Assessed by the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Pain Severity Subscale | The WOMAC is a quality of scale life made up of three domains, pain, stiffness, and disability which each comprising of 5, 2, and 7 questions, respectively. A VAS was used for each subscale. Pain was assessed on a scale of 0-100, with 0 being absolutely no pain and 100 being maximum pain. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Heat Pain Threshold | Contact heat stimuli at non tissue damaging temperatures were delivered using computer driven, peltier-element-based stimulator (Medoc, TSA II), with a 9 cm2 probe applied to the left forearm. The thermode was affixed snugly via Velcro straps to ensure even skin contact and repositioned to an adjacent site after each trial to minimize sensitizationHPTh was assessed on the left ventral forearm using an ascending method of limits paradigm; from a non-painful 32°C baseline, the temperature was steadily increased at 0.5°C/sec. Two trials of heat pain threshold were conducted. Averages of both trials are presented from respective time point below. Subjects push a button when the stimulus "first feels painful" The temperature (degrees Celsius) at the time button is pushed is automatically recorded. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | degrees Celsius | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Heat Pain Tolerance (HPTOL) | Contact heat stimuli at non tissue damaging temperatures were delivered using computer driven, peltier-element-based stimulator (Medoc, TSA II), with a 9 cm2 probe applied to the left forearm. The thermode was affixed snugly via Velcro straps to ensure even skin contact and repositioned to an adjacent site after each trial to minimize sensitization. HPTOL was assessed on the left ventral forearm using an ascending method of limits paradigm; from a non-painful 32°C baseline, the temperature was steadily increased at 0.5°C/sec. Two trials of HPTOL were conducted. An average of both trials at each respective time point is presented below. Subjects push a button when the stimulus "becomes intolerable." The temperature (degrees Celsius) at the time button is pushed to terminate the stimulation is automatically recorded. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | degrees Celsius | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Pressure Pain Threshold | A Somedic algometer was used to assess pressure pain threshold (PPTh) similar to previous studies. The algometer's 1cm2 rubber probe was placed over the muscle belly, with the pressure increased steadily at a constant rate (30kPA/Sec), until the subject indicated that s/he "first felt pain." PPTh was assessed 2 times each, bilaterally, at (in a randomized order) the masseter muscle trapezius muscle, and at the proximal third of the brachioradialis muscle (forearm). The scores from each location were averaged for each participant at that respective time point. The same site was never stimulated consecutively. At least 90 s were maintained between successive stimuli | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | kPA | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Quality of Life as Assessed by the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Disability Subscale | The WOMAC is a quality of scale life made up of three domains, pain, stiffness, and disability which each comprising of 5, 2, and 7 questions, respectively. A VAS was used for each subscale. Disability was assessed on a VAS of 0-100, with 0 being absolutely no disability and 100 being maximum disability. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Quality of Life as Assessed by the Short Form-36 (SF-36) Physical Health Component Summary | The SF-36 is a broad, well normed measure of quality of life, comprised of 36 questions aggregated into 8 domains/dimensions. The Physical Component Summary was used here as a global index of physical health functioning. Scale 0-100, with 0 being worst functional level, 100 being the best. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Quality of Life as Assessed by the Short Form-36 (SF-36) Mental Health Component Summary | The SF-36 is a broad, well normed measure of quality of life, comprised of 36 questions aggregated into 8 domains/dimensions. The Mental Component Summary was used here as a global index of mental health functioning. Scale 0-100, with 0 being worst functional level, 100 being the best. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| Secondary | Joint Stiffness as Assessed by the Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) Joint Stiffness Subscale | The WOMAC is a quality of scale life made up of three domains, pain, stiffness, and disability which each comprising of 5, 2, and 7 questions, respectively. A VAS was used for each subscale. Joint Stiffness was assessed on a VAS scale of 0-20, with 0 being no joint stiffness, and 20 being maximum stiffness. | Data was not included for all participants, as some were unable to complete the task or experienced technical difficulties. | Posted | Mean | Standard Deviation | units on a scale | Mean of baseline, 6 week follow-up and 12 week follow-up |
|
|
|
| 0 |
| 16 |
| 0 |
| 16 |
| 5 |
| 16 |
| EG001 | Eszopiclone | Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks Eszopiclone: 3mg capsule, once daily at bedtime | 0 | 14 | 0 | 14 | 7 | 14 |
| Other Mild to Moderate (Not Recorded) | Product Issues | It is noted that no serious adverse events (AEs) occurred. Only the number of participants who experienced mild to moderate AEs is available & has been reported. However, further information in regards to the specific AE has since been lost. |
|
Not provided
Not provided
Not provided
| D020919 |
| Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D001523 | Mental Disorders |
| D011725 |
| Pyridines |
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up 46 degrees C |
|
|
| 12 week follow-up 46 degrees C |
|
|
| Baseline 48 degrees C |
|
|
| 6 week follow-up 48 degrees C |
|
|
| 12 week follow-up 48 degrees C |
|
|
| Baseline 50 degrees C |
|
|
| 6 week follow-up 50 degrees C |
|
|
| 12 week follow-up 50 degrees C |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 12 week follow-up |
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|
| 6 week follow-up |
|
|
| 12 week follow-up |
|
|